JP2013523733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523733A5 JP2013523733A5 JP2013502610A JP2013502610A JP2013523733A5 JP 2013523733 A5 JP2013523733 A5 JP 2013523733A5 JP 2013502610 A JP2013502610 A JP 2013502610A JP 2013502610 A JP2013502610 A JP 2013502610A JP 2013523733 A5 JP2013523733 A5 JP 2013523733A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically
- dihydroquinolin
- indazol
- methylpiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 3- (7-Methyl-1H-indazol-5-yl) -1- (4- (1-methylpiperidin-4-yl) piperazin-1-yl) -1-oxopropane -2-yl Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 claims 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901510P | 2010-03-30 | 2010-03-30 | |
| US61/319,015 | 2010-03-30 | ||
| PCT/US2011/028168 WO2011123232A1 (en) | 2010-03-30 | 2011-03-11 | Cgrp receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523733A JP2013523733A (ja) | 2013-06-17 |
| JP2013523733A5 true JP2013523733A5 (enExample) | 2014-04-24 |
| JP5908455B2 JP5908455B2 (ja) | 2016-04-26 |
Family
ID=43896902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502610A Active JP5908455B2 (ja) | 2010-03-30 | 2011-03-11 | Ｃｇｒｐ受容体アンタゴニスト |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8481546B2 (enExample) |
| EP (1) | EP2552906B1 (enExample) |
| JP (1) | JP5908455B2 (enExample) |
| KR (3) | KR20180049168A (enExample) |
| CN (1) | CN102834388B (enExample) |
| AR (1) | AR080746A1 (enExample) |
| AU (1) | AU2011233627B2 (enExample) |
| BR (1) | BR112012024785B1 (enExample) |
| CA (1) | CA2794950C (enExample) |
| CL (1) | CL2012002739A1 (enExample) |
| CY (1) | CY1117593T1 (enExample) |
| DK (1) | DK2552906T3 (enExample) |
| EA (1) | EA022815B1 (enExample) |
| ES (1) | ES2562610T3 (enExample) |
| HR (1) | HRP20160287T1 (enExample) |
| HU (1) | HUE028735T2 (enExample) |
| IL (1) | IL221665A (enExample) |
| MX (1) | MX2012010725A (enExample) |
| NZ (1) | NZ603231A (enExample) |
| PE (1) | PE20130340A1 (enExample) |
| PL (1) | PL2552906T3 (enExample) |
| PT (1) | PT2552906E (enExample) |
| RS (1) | RS54608B1 (enExample) |
| SG (1) | SG183918A1 (enExample) |
| SI (1) | SI2552906T1 (enExample) |
| SM (1) | SMT201600078B (enExample) |
| TW (1) | TWI483937B (enExample) |
| WO (1) | WO2011123232A1 (enExample) |
| ZA (1) | ZA201207292B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| WO2020077038A1 (en) * | 2018-10-13 | 2020-04-16 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of cgrp antagonists |
| KR20210116560A (ko) * | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
| SG11202111251SA (en) | 2019-04-11 | 2021-11-29 | R P Scherer Technologies Llc | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
| CN114980862A (zh) * | 2019-12-17 | 2022-08-30 | 拜尔哈文制药股份有限公司 | Cgrp抑制剂的鼻内药物组合物 |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| CA3202137A1 (en) * | 2020-11-19 | 2022-05-27 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| JP2024509165A (ja) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | 片頭痛の治療及び／又は発生の低減 |
| WO2022217008A1 (en) | 2021-04-09 | 2022-10-13 | Teva Czech Industries S.R.O | Solid state forms of zavegepant and process for preparation thereof |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| US20240366618A1 (en) * | 2021-10-11 | 2024-11-07 | Pfizer Ireland Pharmaceuticals | CGRP Antagonists for Treating Trigeminal Neuralgia |
| WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
| US20250276959A1 (en) | 2022-11-09 | 2025-09-04 | Teva Czech Industries S.R.O. | Solid state forms of zavegepant hydrochloride and process for preparation thereof |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
| JP2026515029A (ja) | 2023-04-28 | 2026-05-13 | 成都思倍博医▲薬▼科技有限公司 | オキソピリド脂肪族環又は脂肪族複素環構造を含む化合物及びその医学的使用 |
| WO2025003905A1 (en) | 2023-06-29 | 2025-01-02 | Pfizer Inc. | Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide |
| CN119462607B (zh) * | 2023-08-10 | 2025-11-28 | 南京宁丹新药技术股份有限公司 | 一类喹啉酮衍生物及其用途 |
| EP4781986A1 (en) | 2023-09-21 | 2026-07-29 | Sichuan Purity Pharmaceutical Co., Ltd. | Pharmaceutical composition having improved pharmacokinetic properties |
| CN117551081A (zh) * | 2023-11-13 | 2024-02-13 | 北京康立生医药技术开发有限公司 | 一种偏头痛治疗药物新的制备方法 |
| ES3027457A1 (es) * | 2023-12-13 | 2025-06-13 | Moehs Iberica Sl | Metodo de preparacion de zavegepant, intermedios de sintesis de zavegepant y metodos de preparacion de los mismos |
| IT202400011158A1 (it) | 2024-05-16 | 2025-11-16 | Olon Spa | Processo per preparare (r)-2-ammino-3-(7-metil-1h-indazol-5-il) propanoato di metile, e suo uso come intermedio per la sintesi di zavegepant. |
| WO2026033478A1 (en) | 2024-08-09 | 2026-02-12 | Olon S.P.A. | Process for preparing 3-piperidin-4-il-1h- quinolin-2-one or a salt thereof and its use as an intermediate for the preparation of pharmaceutical active ingredients antagonists of the cgrp peptide receptor |
| CN119306698B (zh) * | 2024-10-09 | 2025-10-21 | 浙江工业大学 | 一种制备扎维吉泮中间体的新方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| ES2616539T3 (es) * | 2002-06-05 | 2017-06-13 | Bristol-Myers Squibb Company | Antagonistas de receptores de péptidos relacionados con el gen de calcitonina |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| CN101495480B (zh) * | 2006-05-03 | 2013-07-10 | 百时美施贵宝公司 | 作为降钙素基因相关肽受体拮抗剂的受限化合物 |
| WO2010006168A2 (en) | 2008-07-09 | 2010-01-14 | University Of Rochester | Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor |
-
2011
- 2011-03-02 US US13/038,550 patent/US8481546B2/en active Active
- 2011-03-11 PE PE2012001746A patent/PE20130340A1/es active IP Right Grant
- 2011-03-11 MX MX2012010725A patent/MX2012010725A/es active IP Right Grant
- 2011-03-11 ES ES11710087.5T patent/ES2562610T3/es active Active
- 2011-03-11 SG SG2012065744A patent/SG183918A1/en unknown
- 2011-03-11 JP JP2013502610A patent/JP5908455B2/ja active Active
- 2011-03-11 BR BR112012024785-9A patent/BR112012024785B1/pt active IP Right Grant
- 2011-03-11 AU AU2011233627A patent/AU2011233627B2/en active Active
- 2011-03-11 CA CA2794950A patent/CA2794950C/en active Active
- 2011-03-11 WO PCT/US2011/028168 patent/WO2011123232A1/en not_active Ceased
- 2011-03-11 KR KR1020187011875A patent/KR20180049168A/ko not_active Ceased
- 2011-03-11 EP EP11710087.5A patent/EP2552906B1/en active Active
- 2011-03-11 KR KR1020177015456A patent/KR101854249B1/ko active Active
- 2011-03-11 DK DK11710087.5T patent/DK2552906T3/en active
- 2011-03-11 PL PL11710087T patent/PL2552906T3/pl unknown
- 2011-03-11 RS RS20160164A patent/RS54608B1/sr unknown
- 2011-03-11 NZ NZ603231A patent/NZ603231A/en unknown
- 2011-03-11 PT PT117100875T patent/PT2552906E/pt unknown
- 2011-03-11 SI SI201130765A patent/SI2552906T1/sl unknown
- 2011-03-11 KR KR1020127028213A patent/KR101747477B1/ko active Active
- 2011-03-11 CN CN201180016888.2A patent/CN102834388B/zh active Active
- 2011-03-11 EA EA201270751A patent/EA022815B1/ru not_active IP Right Cessation
- 2011-03-11 HU HUE11710087A patent/HUE028735T2/en unknown
- 2011-03-11 HR HRP20160287TT patent/HRP20160287T1/hr unknown
- 2011-03-30 AR ARP110101057A patent/AR080746A1/es not_active Application Discontinuation
- 2011-03-30 TW TW100111106A patent/TWI483937B/zh active
-
2012
- 2012-08-27 IL IL221665A patent/IL221665A/en active IP Right Grant
- 2012-09-28 ZA ZA2012/07292A patent/ZA201207292B/en unknown
- 2012-09-28 CL CL2012002739A patent/CL2012002739A1/es unknown
-
2016
- 2016-03-21 SM SM201600078T patent/SMT201600078B/xx unknown
- 2016-03-24 CY CY20161100254T patent/CY1117593T1/el unknown